Added to YB: 2025-08-14
Pitch date: 2025-08-12
HROW [neutral]
Harrow, Inc.
-2.36%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.3B
Pitch Price
$35.98
Price Target
N/A
Dividend
N/A
EV/EBITDA
29.74
P/E
-253.44
EV/Sales
5.49
Sector
Pharmaceuticals
Category
growth
HROW Second Quarter 2025 Earnings results
HROW (earnings update): Q2 revs +30% YOY to $63.7M, GAAP income $5M, Adj EBITDA $17M. VEVYE gaining 3% market share w/ 66% sequential Rx growth, expected to exceed $100M quarterly. Apollo Care alliance accelerating VAFA program. Samsung Bioepis ophthalmology biosimilar acquisition and BYQLOVI add growth. 2025 revenue >$280M with minimal costs.
Read full article (2 min)